Skip to main content
. 2014 Feb 24;5(9):2487–2498. doi: 10.18632/oncotarget.1740
DRScore ≤ −7.62(n = 155) DRScore > −7.62 (n = 51)
Staging I II III I II III
Salmon-Durie 12% 15% 73% 8% 16% 76%
ISS 51% 34% 15% 39% 41% 20%